An HBV-HIV co-infected patient treated with tenofovir-based therapy who achieved HBs antigen/antibody seroconversion.

Abstract

The present report describes a case of a patient with hepatitis B virus (HBV)-human immunodeficiency virus (HIV) co-infection who was treated with tenofovir disoproxil (TDF)-based highly active antiretroviral therapy (HAART) and who achieved HBs antigen (Ag)/antibody (Ab) seroconversion. An 18-year-old Japanese man with HIV and HBV co-infection presented to our hospital. His CD4 count was decreased, and TDF-based HARRT was started. At 30 months after initiation of therapy, HBsAg was not detected. At 36 months after initiation of therapy, HBsAb was detected. We conclude that TDF-based therapy is useful for the management of patients with HBV and HIV co-infection.

• Authors: Takao Watanabe, Yoshio Tokumoto, Masashi Hirooka, Yohei Koizumi, Fujimasa Tada, Hironori Ochi, Masanori Abe, Teru Kumagi, Yoshio Ikeda, Bunzo Matsuura, Kiyonori Takada, Yoichi Hiasa
• Journal: Internal medicine (Tokyo, Japan) (Intern Med) Vol. 53 Issue 12 Pg. 1343-6 ( 2014) ISSN: 1349-7235 [Electronic] Japan
• PMID: 24930654 (Publication Type: Case Reports, Journal Article)

Chemical References

• Anti-HIV Agents
• Hepatitis B Antibodies
• Hepatitis B Surface Antigens
• Organophosphonates
• Tenofovir
• Adenine

Topics

• Adenine (analogs & derivatives, therapeutic use)
• Adolescent
• Anti-HIV Agents (therapeutic use)
• Antiretroviral Therapy, Highly Active
• Coinfection (blood, drug therapy)
• HIV Infections (blood, complications, drug therapy)
• Hepatitis B (blood, complications, drug therapy)
• Hepatitis B Antibodies (blood)
• Hepatitis B Surface Antigens (blood)
• Humans
• Male
• Organophosphonates (therapeutic use)
• Tenofovir